Effects of exercise on circulating tumor cells among patients with resected stage I-III colon cancer

Justin C. Brown, Andrew D. Rhim, Sara L. Manning, Luke Brennan, Alexandra I. Mansour, Anil K. Rustgi, Nevena Damjanov, Andrea B. Troxel, Michael R. Rickels, Bonnie Ky, Babette S. Zemel, Kerry S. Courneya, Kathryn H. Schmitz

1 Dana-Farber Cancer Institute, Boston, MA, United States of America, 2 MD Anderson Cancer Center, Houston, TX, United States of America, 3 University of Michigan Medical School, Ann Arbor, MI, United States of America, 4 University of Pennsylvania, Philadelphia, PA, United States of America, 5 New York University, New York, NY, United States of America, 6 Children's Hospital of Philadelphia, Philadelphia, PA, United States of America, 7 University of Alberta, Edmonton, Alberta, Canada, 8 Penn State College of Medicine, Hershey, PA, United States of America

* justinc_brown@dfci.harvard.edu

Abstract

Background

Physical activity is associated with a lower risk of disease recurrence among colon cancer patients. Circulating tumor cells (CTC) are prognostic of disease recurrence among stage I-III colon cancer patients. The pathways through which physical activity may alter disease outcomes are unknown, but may be mediated by changes in CTCs.

Methods

Participants included 23 stage I-III colon cancer patients randomized into one of three groups: usual-care control, 150 min wk\(^{-1}\) of aerobic exercise (low-dose), and 300 min wk\(^{-1}\) of aerobic exercise (high-dose) for six months. CTCs from venous blood were quantified in a blinded fashion using an established microfluidic antibody-mediated capture device. Poisson regression models estimated the logarithmic counts of CTCs.

Results

At baseline, 78\% (18/23) of patients had \(\geq 1\) CTC. At baseline, older age (\(-0.12\pm 0.06; P = 0.04\)), lymphovascular invasion (0.63\pm 0.25; \(P = 0.012\)), moderate/poor histology (1.09 \(\pm 0.34; P = 0.001\)), body mass index (0.07\pm 0.02; \(P = 0.001\)), visceral adipose tissue (0.08 \(\pm 0.04; P = 0.036\)), insulin (0.06\pm 0.02; \(P = 0.011\)), sICAM-1 (0.04\pm 0.02; \(P = 0.037\)), and sVCAM-1 (0.06\pm 0.03; \(P = 0.045\)) were associated with CTCs. Over six months, significant decreases in CTCs were observed in the low-dose (\(-1.34\pm 0.34; P<0.001\)) and high-dose (\(-1.18\pm 0.40; P = 0.004\)) exercise groups, whereas no significant change was observed in the control group (\(-0.59\pm 0.56; P = 0.292\)). Over six months, reductions in body mass index (\(-0.07\pm 0.02; P = 0.007\)), insulin (\(-0.08\pm 0.03; P = 0.014\)), and sICAM-1 (\(-0.07\pm 0.03; P = 0.005\)) were associated with reductions in CTCs. The main limitations of this proof-of-
concept study are the small sample size, heterogeneous population, and per-protocol statistical analysis.

**Conclusion**

Exercise may reduce CTCs among stage I-III colon cancer patients. Changes in host factors correlated with changes in CTCs. Exercise may have a direct effect on CTCs and indirect effects through alterations in host factors. This hypothesis-generating observation derived from a small pilot study warrants further investigation and replication.

**Introduction**

The development of metastases from colon cancer are hypothesized to result from tumor cells entering the circulation, migrating to distant organs, extravasating, multiplying, and eventually manifesting as clinically-detectable lesions [1]. The early detection and characterization of circulating tumor cells (CTCs) are important to monitor and prevent the development of metastases [2]. CTCs predict disease recurrence and mortality among patients with stage I-III colon cancer [3–6]. For example, among stage III colon cancer patients, the presence of ≥1 CTC(s) after completing post-operative chemotherapy is independently associated with a six-fold increase in the risk of disease recurrence [6].

Exercise after a diagnosis of stage I-III colon cancer may lower the risk of disease recurrence and mortality [7, 8]. However, the biologic or biobehavioral mechanisms through which exercise may improve disease outcomes are not known. Computational models of fluid shear stress demonstrate that shear flow characteristics may affect CTC viability and alter intracellular characteristics of CTCs [9], such that higher forces and longer durations of shear stress exposure may retard growth rates of CTCs and attenuate metastatic potential [10, 11]. Exercise induces substantial increases in vascular shear stress [12, 13], which may alter CTCs in patients with colon cancer. This direct effect of exercise on CTCs may explain, in part, the biological mechanism through which exercise reduces disease recurrence in patients with colon cancer.

In addition, patient or host characteristics related to energy balance [14], such as obesity and hyperinsulinemia, may create an environment that is plentiful in growth factors and impaired immune surveillance necessary to promote the survival and proliferation of CTCs [15], perhaps explaining why states of obesity and hyperinsulinemia are associated with disease recurrence and mortality [16–18]. Exercise reduces visceral obesity and insulin among patients with colon cancer [19, 20]. Exercise may therefore also have indirect effects on CTCs by altering the host tumor microenvironment.

We explored these novel ideas by enumerating CTCs in the setting of a pilot randomized exercise trial among patients with resected stage I-III colon cancer [21]. Given the hypothesis-generating nature of this study, we aimed to characterize: 1) the proportion of colon cancer patients with enumerable CTCs prior to exercise training; 2) demographic, clinical, and host factors that correlated with CTCs prior to exercise training; 3) changes in CTCs after exercise training; and 4) the relationship between changes in host factors (i.e., obesity, insulin) with changes in CTCs.

**Materials and methods**

**Participants**

Detailed methods of this randomized clinical trial have been published [21]. Patients were eligible for participation if they were diagnosed with histologically-proven stage I-III colon cancer; completed
surgical resection and adjuvant chemotherapy within 36 months of entering the study; self-reported participating in <150 min-wk\(^{-1}\) of moderate or vigorous intensity physical activity [22]; were of age ≥18 years; provided written physician approval; had no additional surgery planned within the six-month intervention period; and had the ability to walk unassisted for six minutes.

**Randomization**

Participants were stratified on cancer stage and randomized in equal proportion to one of three groups: low-dose aerobic exercise (150 min-wk\(^{-1}\)), high-dose aerobic exercise (300 min-wk\(^{-1}\)), or usual care control. This study was approved by the University of Pennsylvania Institutional Review Board and registered on Clinicaltrials.gov as NCT02250053. All participants provided informed consent and approval from their physician prior to participation in any study activities.

**Intervention**

Participants randomized to the low-dose or high-dose exercise groups were provided with an in-home treadmill (LifeSpan Fitness, TR1200i, Salt Lake City, UT) and a heart rate monitor (Polar Electro, RS400, Kempele Finland). Exercise intensity was prescribed at 50–70% of the age-predicted maximum heart rate. The low-dose and high-dose groups progressed toward the goal of 150 or 300 min-wk\(^{-1}\) of exercise, respectively. Detailed methods and results of the exercise intervention are published [21, 23]. Over six months, the low-dose group completed 141 min-wk\(^{-1}\) (95% CI: 122–161; 93% adherence) and the high-dose group completed 247 min-wk\(^{-1}\) (95% CI: 226–268; 89% adherence) of exercise. Participants randomized to the usual-care control group were asked to maintain their pre-study levels of physical activity or follow the recommendations provided by their physician.

**Measurements**

Baseline and six-month measurements were obtained by trained staff members who were blinded to treatment assignment. Demographic characteristics including age, sex, and race were self-reported. Smoking status was obtained from a standardized questionnaire [24]. Clinical information including cancer stage, T stage (depth of invasion of the primary tumor), N stage (regional lymph node involvement), treatment with chemotherapy, presence of lymphovascular invasion, and histologic tumor differentiation were obtained from the cancer registry, pathology reports, and physician records.

Body mass index (BMI; kg/m\(^2\)) was calculated using standard anthropometric measures [weight (kg) and height (m)], and dual-energy x-ray absorptiometry was used to quantify visceral adipose tissue [21]. All study participants underwent a fasting blood draw at baseline and follow-up. EDTA-preserved plasma was stored at −80°C. Insulin concentration was quantified using a radioimmunoassay (EMD Millipore, Billerica, MA). Insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein 3 (IGFBP-3), soluble intercellular adhesion molecule 1 (sICAM-1), and soluble vascular adhesion molecule 1 (sVCAM-1) concentrations were quantified using enzyme-linked immunosorbent assays (DSL, Webster, TX, USA for IGF-1 and IGFBP-3; EMD Millipore, Billerica, MA, USA for sICAM-1 and sVCAM-1). Baseline and follow-up samples for each participant were assayed simultaneously and in duplicate at the end of the study. Coefficients of variation for all assays were ≤10%.

**Circulating tumor cell enumeration**

At baseline and follow-up, a sample of 10 mL whole blood was collected in a tube containing 300 μL of Na\(_2\)EDTA. Samples were processed within 72-hours of collection using a
geometrically enhanced differential immunocapture (GEDI) platform [25]. GEDI is a microfluidic device that utilizes obstacles coated with an antibody specific to epithelial cell-adhesion molecule (EpCAM) to capture rare cells within blood. Blood was perfused through the GEDI chip at 1 mL/hr. Captured cells were stained with the nuclear marker DAPI, fluorescently labeled antibodies to the leukocyte marker CD45, and the epithelial cell marker Pdx-1. Using fluorescence microscopy, DAPI+/CD45-/Pdx1+ EpCAM captured cells with intact cellular morphology were counted as CTCs by a technician blinded to randomized treatment assignment. CTC counts are presented per 1 mL of whole blood [26].

Statistical analysis

Descriptive statistics presented for baseline variables include counts and proportions for categorical variables and means ± standard deviations for continuous variables. Categorical baseline characteristics were compared among the three groups using Fisher’s exact test, and continuous baseline characteristics were compared among the three study groups using the Kruskal-Wallis test. The distribution of CTCs (a count outcome) was positively-skewed (P<0.001) with a mean approximately equal to its standard deviation (3.35±3.08). Therefore a series of Poisson regression models were used to estimate CTCs [27]. The Poisson regression model estimates the logarithm of the expected count of CTCs. To evaluate changes in CTCs from baseline to six months in the randomized groups, a random-effects Poisson model was estimated. A negative binomial model was also fit to the data and the results did not differ from those presented herein using Poisson models. We did not adjust our type I error rate for multiplicity. All analyses should be interpreted as exploratory and hypothesis-generating.

Results

The availability of GEDI chips was limited due to our faster than anticipated accrual onto the study protocol. Therefore, 23 of 39 trial participants had both a baseline and six-month CTC enumeration sample available (Fig 1). The proportion of participants with available CTC samples were similar across the three randomized groups (P = 0.127). The 23 participants with available CTC samples were like the 39 participants in the full study sample (S1 Table), with the exception that IGF-1 was lower in participants with CTC enumeration (4.13±0.30 vs 4.03±0.23; P = 0.032).

The average age of study participants was 55.9±9.3 years. Most patients had stage II (35%) or stage III (52%) colon cancer, and 74% were treated with chemotherapy (all chemotherapy regimens included a fluoropyrimidine and oxaliplatin). Patients completed cancer therapy a median of eight months prior to study enrollment (range: 1−21 months).

At baseline, 78% (18/23) of patients had ≥1 CTC, 65% (15/23) had ≥2 CTCs, and 48% (11/23) had ≥3 CTCs per 1 mL of whole blood. The median number of CTCs was 2 [interquartile range: 1−6] and ranged from 0 to 10. In cross-sectional baseline analyses, several characteristics were associated with CTCs (Table 1). Older age was associated with fewer CTCs (−0.12±0.06; P = 0.043). Tumors with moderate or poor histologic differentiation (1.09±0.34; P = 0.001) and lymphovascular invasion (0.63±0.25; P = 0.012) were associated with more CTCs. Higher BMI (0.07±0.02; P = 0.001), visceral adipose tissue (0.08±0.04; P = 0.036), insulin (0.06±0.02; P = 0.011), sICAM-1 (0.04±0.02; P = 0.037), and sVCAM-1 (0.06±0.03; P = 0.045) were associated with more CTCs.

Baseline characteristics of the 23 participants were balanced across randomized groups, with exception of insulin (P = 0.053) and sICAM-1 (P = 0.049; Table 2). Average CTCs at baseline were not statistically significantly different among the three groups (P = 0.404), though the control group had numerically fewer CTCs compared with the two exercise groups.
Table 3). Categorically, the proportion of patients with \( \geq 1 \) \((P = 0.657)\), \( \geq 2 \) \((P = 0.236)\), and \( \geq 3 \) \((P = 0.740)\) CTCs were similar among the three groups.

Compared with baseline, statistically significant decreases in CTCs were observed in the low-dose \((-1.34 \pm 0.34; P < 0.001)\) and high-dose \((-1.18 \pm 0.40; P = 0.004)\) exercise groups, whereas no significant change was observed in the control group \((-0.59 \pm 0.56; P = 0.292)\). When we adjusted for insulin or sICAM-1 (due to baseline imbalances), our effect estimates were not altered.

In longitudinal analyses that consolidated the three randomized groups, reductions in BMI \((-0.07 \pm 0.02; P = 0.007)\), insulin \((-0.08 \pm 0.03; P = 0.014)\), and sICAM-1 \((-0.07 \pm 0.03; P = 0.005)\) were associated with reductions in CTCs (Table 4).

**Discussion**

In this pilot study, six months of moderate-intensity aerobic exercise at doses of 150 and 300 min wk\(^{-1}\) among stage I-III colon cancer patients resulted in significant reductions from baseline in CTCs. In addition, reductions in BMI, insulin, and sICAM-1 were correlated with reductions in CTCs. Using the GEDI microfluidic platform, 78% of patients had \( \geq 1 \) CTC, which is higher than previously published rates of 10–25% in stage I-III in colon cancer patients [3, 5, 6]. GEDI detects up to 400-fold more CTCs than alternative platforms [25], which has been utilized in prior studies in colon cancer and may have a greater dynamic range.
for detection and discrimination [3]. The results from this study may help to provide insight to potential new mechanisms through which exercise may improve disease outcomes among

Table 1. Characteristics associated with CTCs at baseline (n = 23).

| Characteristic                     | Total Sample Mean or Count (%) | CTCs (LS Mean ± SE) | P     |
|-----------------------------------|--------------------------------|----------------------|-------|
| **Demographic**                   |                                |                      |       |
| Age, years                        | 55.9±9.3                       | -0.12±0.06<sup>a</sup> | 0.043 |
| Sex                               |                                |                      |       |
| Male                              | 7 (30%)                        | 0.00—Referent        | —     |
| Female                            | 16 (70%)                       | -0.43±0.23           | 0.063 |
| Race                              |                                |                      |       |
| White                             | 19 (83%)                       | 0.00—Referent        | —     |
| Black/Other                       | 4 (17%)                        | -0.60±0.37           | 0.110 |
| **Smoking History**               |                                |                      |       |
| Never                             | 11 (48%)                       | 0.00—Referent        | —     |
| Former/Current                    | 12 (52%)                       | -0.22±0.23           | 0.342 |
| **Tumor & Treatment**             |                                |                      |       |
| Stage                             |                                |                      |       |
| I                                 | 3 (13%)                        | 0.00—Referent        | —     |
| II                                | 8 (35%)                        | -0.05±0.36           | 0.896 |
| III                               | 12 (52%)                       | -0.15±0.34           | 0.669 |
| T Stage                           |                                |                      |       |
| T1-T2                             | 3 (13%)                        | 0.00—Referent        | —     |
| T3                                | 14 (61%)                       | -0.33±0.34           | 0.340 |
| T4                                | 6 (26%)                        | 0.28±0.35            | 0.435 |
| N Stage                           |                                |                      |       |
| N0                                | 11 (48%)                       | 0.00—Referent        | —     |
| N1-2                              | 12 (52%)                       | -0.11±0.23           | 0.620 |
| Chemotherapy                      | 17 (74%)                       | 0.15±0.27            | 0.588 |
| Time Since Treatment Completion, Months | 9.0±6.1                      | -0.008±0.02          | 0.662 |
| Lymphovascular Invasion           | 9 (43%)                        | 0.63±0.25            | 0.012 |
| Differentiation                   |                                |                      |       |
| Well                              | 4 (17%)                        | 0.00—Referent        | —     |
| Moderate/Poor                     | 10 (44%)                       | 1.09±0.34            | 0.001 |
| Unknown                           | 9 (39%)                        | 1.07±0.29            | <0.001|
| **Anthropometrics**               |                                |                      |       |
| BMI, kg/m<sup>2</sup>             | 30.2±5.5                       | 0.07±0.02<sup>b</sup> | 0.001 |
| Visceral Adipose Tissue, cm<sup>2</sup> | 127.4±56.8               | 0.08±0.04<sup>c</sup> | 0.036 |
| **Plasma Concentrations**        |                                |                      |       |
| Insulin                           | 2.70±0.55                      | 0.06±0.02<sup>d</sup> | 0.011 |
| IGF-1                             | 4.03±0.23                      | -0.01±0.05<sup>d</sup> | 0.763 |
| IGFBP-3                           | 7.62±0.26                      | -0.09±0.05<sup>d</sup> | 0.054 |
| sICAM-1                           | 5.82±0.60                      | 0.04±0.02<sup>d</sup> | 0.037 |
| sVCAM-1                           | 6.91±0.38                      | 0.06±0.03<sup>d</sup> | 0.045 |

<sup>a</sup>Per 5 years of age  
<sup>b</sup>Per 1 kg/m<sup>2</sup> of BMI  
<sup>c</sup>Per 20 cm<sup>2</sup> of visceral adipose tissue  
<sup>d</sup>Per 0.1 unit increase in log-transformed geometric mean  

https://doi.org/10.1371/journal.pone.0204875.t001
patients with colon cancer. The discussion herein outlines hypotheses about how exercise may reduce CTCs.

Exercise may have a direct effect on CTCs. We observed significant decreases in CTCs in the two exercise groups, whereas no significant decrease was observed among the control group. Experimental models of shear stress may provide insight to these findings. A shear

Table 2. Characteristics between study groups at baseline.

| Characteristic               | Control (n = 5) | Low-Dose (n = 11) | High-Dose (n = 7) | P     |
|-----------------------------|----------------|-------------------|------------------|-------|
| **Demographic**             |                |                   |                  |       |
| Age, years                  | 55.6±4.3       | 58.4±9.6          | 52.1±11.2        | 0.399 |
| Sex, %                      |                |                   |                  |       |
| Male 0 (0%)                 | 0 (0%)         | 5 (45%)           | 2 (29%)          | 0.220 |
| Female 5 (100%)             | 6 (55%)        | 5 (71%)           |                  |       |
| Race, %                     |                |                   |                  |       |
| White 4 (80%)               | 4 (80%)        | 9 (82%)           | 6 (86%)          | 0.999 |
| Black/Other 1 (20%)         | 1 (20%)        | 2 (18%)           | 1 (14%)          |       |
| Smoking History, %          |                |                   |                  |       |
| Never 3 (60%)               | 3 (60%)        | 4 (36%)           | 4 (57%)          | 0.641 |
| Former/Current 2 (40%)      | 2 (40%)        | 7 (64%)           | 3 (43%)          |       |
| **Tumor & Treatment**       |                |                   |                  |       |
| Stage, %                    |                |                   |                  |       |
| I 0 (0%)                    | 0 (0%)         | 2 (18%)           | 1 (14%)          | 0.826 |
| II 1 (20%)                  | 1 (20%)        | 4 (36%)           | 3 (43%)          |       |
| III 4 (80%)                 | 4 (80%)        | 5 (45%)           | 3 (43%)          |       |
| T Stage, %                  |                |                   |                  |       |
| T1-T2 0 (0%)                | 0 (0%)         | 2 (18%)           | 1 (14%)          | 0.924 |
| T3 3 (60%)                  | 3 (60%)        | 7 (64%)           | 4 (57%)          |       |
| T4 2 (40%)                  | 2 (40%)        | 2 (18%)           | 2 (29%)          |       |
| N Stage, %                  |                |                   |                  |       |
| N0 1 (20%)                  | 1 (20%)        | 6 (55%)           | 4 (57%)          | 0.484 |
| N1-2 4 (80%)                | 4 (80%)        | 5 (45%)           | 3 (43%)          |       |
| Chemotherapy, %             |                |                   |                  |       |
| 5 (100%)                    | 5 (100%)       | 7 (64%)           | 5 (71%)          | 0.390 |
| Time Since Treatment Completion, Months | 8 [3–12] | 7 [4–11] | 9 [5–17] | 0.761 |
| Lymphovascular Invasion     | 1 (20%)        | 5 (56%)           | 3 (43%)          | 0.470 |
| Differentiation             |                |                   |                  |       |
| Well 1 (20%)                | 1 (20%)        | 3 (27%)           | 0 (0%)           | 0.659 |
| Moderate/Poor 2 (40%)       | 2 (40%)        | 5 (45%)           | 3 (43%)          |       |
| Unknown 2 (40%)             | 2 (40%)        | 3 (27%)           | 4 (57%)          |       |
| **Anthropometrics**         |                |                   |                  |       |
| BMI 29.3±4.9                | 28.6±3.9       | 33.3±7.3          | 0.366            |
| Visceral Adipose Tissue     | 97.4±53.4      | 123.4±43.1        | 154.9±71.8       | 0.299 |
| **Plasma Concentrations**   |                |                   |                  |       |
| Insulin, pmol/L*            | 2.33±0.24      | 2.75±0.37         | 2.88±0.82        | 0.053 |
| IGF-1, ng/mL*               | 4.01±0.28      | 4.03±0.20         | 4.04±0.27        | 0.987 |
| IGFBP-3, ng/mL*             | 7.49±0.16      | 7.59±0.21         | 7.74±0.36        | 0.304 |
| ICAM-1, ng/mL*              | 5.14±0.64      | 6.05±0.31         | 5.95±0.64        | 0.049 |
| sVCAM-1, ng/mL*             | 6.71±0.33      | 7.08±0.41         | 6.77±0.23        | 0.152 |

*aLog-transformed geometric mean

https://doi.org/10.1371/journal.pone.0204875.t002

Exercise and circulating tumor cells
stress of 0.4 dyn/cm² reduces the viability and increases the amount of apoptotic cells in a colon cancer cell line when compared to static conditions [28]. Higher magnitudes of shear stress, 1–2 dyn/cm², induces a more pronounced decrease in cell viability and increases apoptosis compared to static conditions, suggesting that the sensitization of cancer cells to apoptosis occurs in a dose-dependent fashion that is proportional to the magnitude of shear stress [28]. Moderate-intensity exercise in humans (at ~55% of the age-predicted maximum heart rate) produces shear stresses of 5.2–6.2 dyn/cm² [13], and increases proportionally with exercise intensity [12]. In a colon cancer cell line, increasing the duration of exposure, from 10 to 120 minutes, at a fixed 2 dyn/cm² shear stress, also reduces cell viability and increases apoptosis in a dose-dependent fashion that is proportional to the duration of shear stress exposure [28]. However, we did not observe a dose-response relationship with respect to volume, as 150 min-wk⁻¹ reduced CTCs to a similar extent at 300 min-wk⁻¹ of exercise. It is plausible that 150 min-wk⁻¹ may be a sufficient exercise volume to reduce CTCs. These data suggest that exercise may reduce CTCs via mechanical forces. Our finding that exercise lowers CTCs is consistent with prospective cohort studies that suggest moderate or vigorous intensity exercise (high shear stress exposure) and larger volumes of exercise (long exposure to a given shear stress, e.g., 150 min-wk⁻¹) are associated with a lower risk of disease recurrence [8]. These data may explain, in part, a direct biological or mechanical mechanism through which exercise reduces disease recurrence in colon cancer patients.

Exercise may have indirect effects on CTCs through alterations in the host or patient tumor microenvironment. We observed that reductions in BMI, insulin, and sICAM-1 were significantly correlated with reductions in CTCs over six months. In vivo and preclinical studies support these findings. Exposure of colon cancer cells to adipocytes and pre-adipocytes significantly increases cell proliferation [29], and in a mouse model, the surgical removal of visceral obesity reduces the development and slows the progression of colonic tumors and prolongs survival [30]. Hyperinsulinemia increases colon cancer cell resistance to 5-fluorouracil [31], and oxaliplatin chemotherapy [31, 32], and exposure to insulin promotes colonic tumor

Table 3. Effects of exercise on CTCs.

| CTC count per 1 mL blood | Control | Low-Dose | High-Dose |
|-------------------------|---------|----------|-----------|
| Baseline, Mean ± SD     | 1.8±3.5 | 3.8±3.5  | 3.7±2.8   |
| Change, LS Mean ± SE   | −0.59±0.56 | −1.34±0.34 | −1.18±0.40 |
| P                       | 0.292   | <0.001   | 0.004     |

Table 4. Relationship between change in anthropometric and plasma concentrations and change in CTCs during six months among all participants (n = 23).

| Characteristic                  | Unit of Change | Δ in CTCs (LS Mean ± SE) | P      |
|--------------------------------|----------------|--------------------------|--------|
| BMI                            | −1.0 kg/m²     | −0.07±0.02               | 0.007  |
| Visceral Adipose Tissue        | −20.0 cm²      | −0.10±0.06               | 0.121  |
| Insulin                        | −0.1*          | −0.08±0.03               | 0.014  |
| IGF-1                          | −0.1*          | 0.04±0.05                | 0.419  |
| IGFBP-3                        | −0.1*          | 0.06±0.06                | 0.278  |
| sICAM-1                        | −0.1*          | −0.07±0.03               | 0.005  |
| sVCAM-1                        | −0.1*          | 0.03±0.04                | 0.294  |

LS Mean, least squares mean; SE, standard error.
*Change per 0.1 unit decrease in geometric mean

https://doi.org/10.1371/journal.pone.0204875.t003

https://doi.org/10.1371/journal.pone.0204875.t004
multiplicity [33]. sICAM-1 is associated with obesity and hyperinsulinemia [34], and exposure to sICAM-1 stimulates tumor growth [35], and the inhibition of sICAM-1 attenuates colonic tumor cell invasion [36]. These in vivo and preclinical data are supported by prospective cohort studies that suggest higher BMI and visceral obesity [16, 18], hyperinsulinemia [17], and elevated sICAM-1 [37] are associated with recurrence and survival among patients with colon cancer. Exercise reduces visceral obesity in linear dose-response fashion [19], and insulin and sICAM-1 are reduced in nonlinear fashion [20, 23]. Collectively, these data may explain, in part, an indirect biological mechanism or mediator of exercise, such that the host tumor microenvironment is favorably altered by reducing available growth factors and improvement of immune system function [15], suppressing the growth of tumors that give rise to CTCs, and potentially reducing disease recurrence in colon cancer patients.

Additional research is needed to replicate our hypothesis-generating findings and begin to provide clinical context to these data. Changes in CTCs in response to an intervention, such as exercise, might represent an intermediate efficacy endpoint [38]. In the metastatic setting, changes in CTCs often precede radiologic progression, increasing the promise of CTCs for use as an endpoint [38]. However, less is known about the use of CTCs in the early-stage setting, and fundamental questions remain unanswered. It is unknown how many CTCs are needed to classify a patient at high-risk for disease recurrence. Studies have used thresholds of $\geq 1$, $\geq 2$, $\geq 3$ CTCs to classify patients at high-risk of disease recurrence. While CTCs in the early-stage setting have been shown to be prognostic, it is unknown if reducing CTCs lowers the risk of disease recurrence (i.e., are CTCs a valid surrogate of disease recurrence and overall survival).

If CTCs are valid as a surrogate endpoint in the early-stage setting [39, 40], then studies are needed to determine which lifestyle behaviors best reduce CTCs, and the minimal required reduction in CTCs that is necessary to lower the risk of disease recurrence. Examining the comparative importance of reducing CTCs through mechanical forces (i.e., exercise) versus altering the tumor microenvironment exclusively (i.e., weight loss through caloric restriction) is a reasonable line of inquiry. It is plausible that the combination of exercise and weight loss may possess synergistic effects to reduce CTCs through the combination of mechanical forces from exercise and alterations in the tumor microenvironment from weight loss. Studies are needed to examine this hypothesis. The pairing of lifestyle interventions with pharmacological therapies such as aspirin, which inhibits platelet aggregation decreasing the ability for CTCs to bind to the endothelium (i.e., altering the mechanical efficiency of extravasation) [41], or metformin to reduce insulin (i.e., altering the host tumor microenvironment through growth factor suppression) [42], warrant investigation as synergy may exist between two complementary interventions.

There are several limitations to this study. The size of our study population was very small, which reduces the reliability of our findings. Because of the limited availability of GEDI chips, only 23 of 39 participants were analyzed, which may compromise randomization. We acknowledge that the control group had numerically fewer CTCs at baseline. Studies with larger sample sizes are needed to confirm that exercise reduces CTCs. This study should be interpreted with hypothesis-generating implications. We did not recruit patients based on having enumerable CTCs at baseline. Study participants were younger than the population from which they were recruited [21]. Therefore, the finding that older age at baseline was associated with fewer CTCs may be a statistical artifact of our study cohort. Alternatively, because of the enrichment with younger individuals in our sample, our study may overestimate the prevalence of CTCs in the population (78%). We tested a moderate intensity of exercise (50–70% of the age predicted maximum heart rate) at two distinct volumes (150 and 300 min·wk$^{-1}$). It is unknown how varying the exercise intensity would alter CTCs. We studied the chronic effects of exercise. It is unknown if reductions in CTCs occur after an acute bout of exercise or only
after chronic exercise training. It is unknown what happens to CTCs upon the cessation of exercise. We are unable to determine the source of CTCs. It is unknown if the identified CTCs were shed from the primary tumor prior to surgical resection or are from established distant micro-metastatic foci that are not yet clinically detectable. The median time from finishing cancer therapy in our sample was eight months, therefore both scenarios are plausible. As this was considered an exploratory and hypothesis-generating study, we did not adjust our type I error rate for multiplicity.

There are several strengths to this study. We used the GEDI microfluidic platform, which has a high sensitivity to detect CTCs [25]. The enumeration of CTCs was completed by a technician who was blinded to treatment assignment. Adherence to both exercise doses of exercise was 90% and confirmed with objective monitoring. Most our study sample received chemotherapy, suggesting the population was at elevated risk of experiencing disease recurrence. Therefore, the population sample is ideal to study the effects of exercise on CTCs.

In conclusion, exercise may lower CTCs in patients with resected stage I-III colon cancer. The findings from this pilot study may be useful to begin to unravel the biologic or biobehavioral mechanisms through which exercise may reduce the risk of disease recurrence among patients with colon cancer. This hypothesis-generating observation warrants further investigation and replication.

Supporting information

**S1 Checklist.** CONSORT 2010 checklist.
(DOC)

**S1 Table.** Comparison between full study sample and CTC subsample at baseline.
(DOCX)

**S1 Protocol.** Study protocol.
(DOCX)

**S1 Data.** Public data (limited dataset).
(XLS)

Author Contributions

**Conceptualization:** Justin C. Brown, Andrew D. Rhim, Anil K. Rustgi, Nevena Damjanov, Andrea B. Troxel, Michael R. Rickels, Bonnie Ky, Babette S. Zemel, Kerry S. Courneya, Kathryn H. Schmitz.

**Data curation:** Justin C. Brown, Andrew D. Rhim, Sara L. Manning, Luke Brennan, Alexandra I. Mansour, Andrea B. Troxel, Michael R. Rickels, Bonnie Ky, Babette S. Zemel, Kerry S. Courneya, Kathryn H. Schmitz.

**Formal analysis:** Justin C. Brown, Sara L. Manning, Luke Brennan, Alexandra I. Mansour, Anil K. Rustgi, Nevena Damjanov, Andrea B. Troxel, Michael R. Rickels, Bonnie Ky, Babette S. Zemel, Kerry S. Courneya, Kathryn H. Schmitz.

**Funding acquisition:** Justin C. Brown, Andrea B. Troxel, Michael R. Rickels, Kathryn H. Schmitz.

**Investigation:** Justin C. Brown, Andrew D. Rhim, Sara L. Manning, Luke Brennan, Alexandra I. Mansour, Anil K. Rustgi, Nevena Damjanov, Andrea B. Troxel, Michael R. Rickels, Bonnie Ky, Kerry S. Courneya, Kathryn H. Schmitz.
Methodology: Justin C. Brown, Andrew D. Rhim, Anil K. Rustgi, Nevena Damjanov, Andrea B. Troxel, Michael R. Rickels, Bonnie Ky, Babette S. Zemel, Kerry S. Courneya, Kathryn H. Schmitz.

Project administration: Justin C. Brown, Kathryn H. Schmitz.

Resources: Justin C. Brown, Andrew D. Rhim, Kathryn H. Schmitz.

Software: Justin C. Brown, Andrea B. Troxel, Kathryn H. Schmitz.

Supervision: Justin C. Brown, Andrew D. Rhim, Sara L. Manning, Nevena Damjanov, Michael R. Rickels, Kathryn H. Schmitz.

Validation: Justin C. Brown, Sara L. Manning, Luke Brennan, Alexandra I. Mansour, Andrea B. Troxel, Babette S. Zemel, Kathryn H. Schmitz.

Visualization: Justin C. Brown, Sara L. Manning, Luke Brennan, Alexandra I. Mansour, Andrea B. Troxel, Babette S. Zemel, Kathryn H. Schmitz.

Writing – original draft: Justin C. Brown.

Writing – review & editing: Justin C. Brown, Andrew D. Rhim, Sara L. Manning, Luke Brennan, Alexandra I. Mansour, Anil K. Rustgi, Nevena Damjanov, Andrea B. Troxel, Michael R. Rickels, Bonnie Ky, Babette S. Zemel, Kerry S. Courneya, Kathryn H. Schmitz.

References

1. Maheswaran S, Haber DA. Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev. 2010; 20(1):96–9. https://doi.org/10.1016/j.gde.2009.12.002 PMID: 20071161

2. Joosse SA, Gorges TM, Pantel K. Biology, detection, and clinical implications of circulating tumor cells. EMBO Mol Med. 2015; 7(1):1–11. Epub 2014/11/16. https://doi.org/10.15252/emmm.201303698 PMID: 25398926; PubMed Central PMCID: PMCPMC4309663.

3. Bork U, Rahbari NN, Scholch S, Reissfelder C, Kahlert C, Buchler MW, et al. Circulating tumour cells and outcome in non-metastatic colorectal cancer: a prospective study. Br J Cancer. 2015; 112 (8):1306–13. Epub 2015/04/14. https://doi.org/10.1038/bjc.2015.88 PMID: 25867263; PubMed Central PMCID: PMCPMC4402459.

4. Galizia G, Gemei M, Orditura M, Romano C, Zamboli A, Castellano P, et al. Postoperative detection of circulating tumor cells predicts tumor recurrence in colorectal cancer patients. J Gastrointest Surg. 2013; 17(10):1809–18. Epub 2013/07/03. https://doi.org/10.1007/s11605-013-2258-6 PMID: 23813048.

5. Inuma H, Watanabe T, Mimori K, Adachi M, Hayashi N, Tamura J, et al. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes’ stage B and C colorectal cancer. J Clin Oncol. 2011; 29(12):1547–55. Epub 2011/03/23. https://doi.org/10.1200/JCO.2010.30.5151 PMID: 21422427.

6. Lu C, Tsai H, Uen Y, Hu H, Chen C, Cheng T, et al. Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer. Br J Cancer. 2013; 108(4):791–7. https://doi.org/10.1038/bjc.2012.595 PMID: 23422758.

7. Je Y, Jeon JY, Giovannucci EL, Meyerhardt JA. Association between physical activity and mortality in colorectal cancer: a meta-analysis of prospective cohort studies. Int J Cancer. 2013; 133(8):1905–13. https://doi.org/10.1002/ijc.28206 PMID: 23590314.

8. Schmid D, Leitzmann M. Association between physical activity and mortality among breast cancer and colorectal cancer survivors: a systematic review and meta-analysis. Ann Oncol. 2014; 25(7):1293–311. https://doi.org/10.1093/annonc/mdu012 PMID: 24644304.

9. Mitchell MJ, King MR. Computational and experimental models of cancer cell response to fluid shear stress. Front Oncol. 2013; 3:44. Epub 2013/03/08. https://doi.org/10.3389/fonc.2013.00044 PMID: 23467856; PubMed Central PMCID: PMCPMC3587800.

10. Fan R, Emery T, Zhang Y, Xia Y, Sun J, Wan J. Circulatory shear flow alters the viability and proliferation of circulating colon cancer cells. Sci Rep. 2016; 6:27073. Epub 2016/06/04. https://doi.org/10.1038/srep27073 PMID: 27255403; PubMed Central PMCID: PMCPMC4891768.
11. Jain RK, Martin JD, Stylianopoulos T. The role of mechanical forces in tumor growth and therapy. Annu Rev Biomed Eng. 2014; 16:321–46. Epub 2014/07/12. https://doi.org/10.1146/annurev-bioeng-071813-105259 PMID: 25041786; PubMed Central PMCID: PMCPMC4109025.

12. Tanaka H, Shimizu S, Ohmori F, Muraoka Y, Kumagai M, Yoshizawa M, et al. Increases in blood flow and shear stress to nonworking limbs during incremental exercise. Med Sci Sports Exerc. 2006; 38(1):81–5. Epub 2006/01/06. PMID: 16394957.

13. Taylor CA, Cheng CP, Espinosa LA, Tang BT, Parker D, Herfkens RJ. In vivo quantification of blood flow and wall shear stress in the human abdominal aorta during lower limb exercise. Ann Biomed Eng. 2002; 30(3):402–8. Epub 2002/06/08. PMID: 12051624.

14. Brown JC, Meyerhardt JA. Obesity and Energy Balance in GI Cancer. J Clin Oncol. 2016; 34(35):4217–24. Epub 2016/12/03. https://doi.org/10.1200/JCO.2016.66.8699 PMID: 27903148; PubMed Central PMCID: PMCPMC5544430.

15. Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc Nutr Soc. 2012; 71(1):181–9. Epub 2011/11/05. https://doi.org/10.1017/S002966511100320X PMID: 22051112.

16. Sinicrope FA, Foster NR, Yethers G, Benson A, Seitz JF, Labianca R, et al. Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy. Cancer. 2013; 119(8):1528–36. https://doi.org/10.1002/cncr.2310947.

17. Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, et al. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol. 2009; 27(2):176–85. Epub 2008/12/10. https://doi.org/10.1200/JCO.2008.17.9945 PMID: 19064975; PubMed Central PMCID: PMCPMC2645084.

18. Xiao J, Mazurak VC, Obiehuyi TA, Caan BJ, Prado CM. Visceral adiposity and cancer survival: a review of imaging studies. Eur J Cancer Care (Engl). 2018; 27(2):e12611. Epub 2016/12/07. https://doi.org/10.1111/ecc.12611 PMID: 27921375.

19. Brown JC, Zemel BS, Troxel AB, Rickels MR, Damjanov N, Ky B, et al. Dose-response effects of aerobic exercise on body composition among colon cancer survivors: a randomised controlled trial. Br J Cancer. 2017; 117(11):1614–20. Epub 2017/09/22. https://doi.org/10.1038/bjc.2017.339 PMID: 28934762; PubMed Central PMCID: PMCPMC5729439.

20. Brown JC, Rickels MR, Troxel AB, Zemel BS, Damjanov N, Ky B, et al. Dose-response effects of exercise on insulin among colon cancer survivors. Endoor Relat Cancer. 2018; 25(1):11–9. Epub 2017/10/12. https://doi.org/10.1530/ERC-17-0377 PMID: 29018055; PubMed Central PMCID: PMCPMC5736434.

21. Brown JC, Troxel AB, Ky B, Damjanov N, Zemel BS, Rickels MR, et al. A randomized phase II dose-response exercise trial among colon cancer survivors: Purpose, study design, methods, and recruitment results. Contemp Clin Trials. 2016; 47:366–75. https://doi.org/10.1016/j.cct.2016.03.001 PMID: 26970181.

22. Paffenbarger R, Wing A, Hyde R. Paffenbarger physical activity questionnaire. Am J Epidemiol. 1978; 108:161–75. PMID: 707484.

23. Brown JC, Troxel AB, Ky B, Damjanov N, Zemel BS, Rickels MR, et al. Dose-Response Effects of Aerobic Exercise Among Colon Cancer Survivors: A Randomized Phase II Trial. Clin Colorectal Cancer. 2018; 17(1):32–40. Epub 2017/07/04. https://doi.org/10.1016/j.clcc.2017.06.001 PMID: 28669606; PubMed Central PMCID: PMCPMC5733693.

24. Epub 2016/12/03. https://doi.org/10.1200/JCO.2016.66.8699 PMID: 27903148; PubMed Central PMCID: PMCPMC5544430.

25. Pleis JR, Lucas JW, Ward BW. Summary health statistics for US adults: National Health Interview Survey, 2008. Vital and health statistics Series 10, Data from the National Health Survey. 2009;(242):1–157. PMID: 20821903.

26. Kirby BJ, Jodari M, Loftus MS, Gaskar G, Pratt ED, Chanel-Vos C, et al. Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One. 2012; 7(4):e35976. Epub 2012/05/05. https://doi.org/10.1371/journal.pone.0035976 PMID: 22558290; PubMed Central PMCID: PMCPMC3338784.

27. Kim DH, Song KH, Sung HK, Do JY, Kim H, Yoon JS, et al. Detection of circulating tumor cells using a novel method. J Biomed Biotechnol. 2012; 2012:230538. https://doi.org/10.1155/2012/230538.

28. Powles J, Thomas GB, Forster J, Sawyers CL, de Bono JS, Floor TS, et al. A randomized phase III study comparing docetaxel plus estramustine versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2004; 22(16):3260–6. https://doi.org/10.1200/JCO.2003.12.417470.

29. Rosner B. Fundamentals of biostatistics: Nelson Education; 2015.

30. Mitchell MJ, King MR. Fluid Shear Stress Sensitizes Cancer Cells to Receptor-Mediated Apoptosis via Trimeric Death Receptors. New J Phys. 2013; 15(1):015008. Epub 2013/01/18. https://doi.org/10.1088/1367-2630/15/1/015008 PMID: 25110459; PubMed Central PMCID: PMCPMC4127470.

31. Amemori S, Ootani A, Aoki S, Fujise T, Shimoda R, Kakimoto T, et al. Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. Am J Physiol Gastroint Liver Physiol. 2007; 292(3):G923–9. Epub 2006/12/16. https://doi.org/10.1152/ajpgi.00415.2006 PMID: 17170030.
30. Huffman DM, Augenlicht LH, Zhang X, Lofrese JJ, Atzmon G, Chamberland JP, et al. Abdominal obesity, independent from caloric intake, accounts for the development of intestinal tumors in Apc1638N/+ female mice. Cancer Prevention Research. 2013; 6(3):177–87. https://doi.org/10.1158/1940-6207.CAPR-12-0414 PMID: 23466815

31. Chen J, Huang XF, Qiao L, Katsifis A. Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. J Gastrointest Oncol. 2011; 2(1):27–33. Epub 2011/03/01. https://doi.org/10.3978/j.issn.2078-6891.2010.028 PMID: 22811824; PubMed Central PMCID: PMC3397588.

32. Volkova E, Robinson BA, Willis J, Currie MJ, Dachs GU. Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells. Oncol Lett. 2014; 7(2):311–20. https://doi.org/10.3892/ol.2013.1710 PMID: 24396438

33. Tran TT, Medline A, Bruce WR. Insulin promotion of colon tumors in rats. Cancer Epidemiol Biomarkers Prev. 1996; 5(12):1013–5. Epub 1996/12/01. PMID: 8959325.

34. Leinonen E, Hurt-Camejo E, Wiklund O, Hulten LM, Hiukka A, Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis. 2003; 166(2):387–94. Epub 2003/01/22. PMID: 12535753.

35. Gho YS, Kim PN, Li HC, Elkin M, Kleinman HK. Stimulation of tumor growth by human soluble intercellular adhesion molecule-1. Cancer Res. 2001; 61(10):4253–7. Epub 2001/05/19. PMID: 11358852.

36. Howard K, Lo KK, Ao L, Gamboni F, Edli BH, Schulick R, et al. Intracellular adhesion molecule-1 mediates murine colon adenocarcinoma invasion. J Surg Res. 2014; 187(1):19–23. Epub 2013/12/24. https://doi.org/10.1016/j.jss.2013.11.001 PMID: 24360118; PubMed Central PMCID: PMCPMC4844553.

37. Alexioud D, Karayiannakis AJ, Syrigos KN, Zbar A, Kremmyda A, Bramis I, et al. Serum levels of E-selectin, ICAM-1 and VCAM-1 in colorectal cancer patients: correlations with clinicopathological features, patient survival and tumour surgery. Eur J Cancer. 2001; 37(18):2392–7. Epub 2001/11/27. PMID: 11720833.

38. Parkinson DR, Dracopoli N, Petty BG, Compton C, Cristofanilli M, Deisseroth A, et al. Considerations in the development of circulating tumor cell technology for clinical use. J Transl Med. 2012; 10(1):138.

39. Atkinson AJ, Colburn WA, DeGruttola VG, DeMets DL. Surrogate endpoints: Preferred definitions and conceptual framework* Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework. Clinical Pharmacology & Therapeutics2001. 2001; 69:89–95.

40. Buyse M, Sargent DJ, Grothey A, Matheson A, de Gramont A. Biomarkers and surrogate end points—the challenge of statistical validation. Nat Rev Clin Oncol. 2010; 7(6):309–17. Epub 2010/04/07. https://doi.org/10.1038/nrclonc.2010.43 PMID: 20368727.

41. Uppal A, Wightman SC, Ganai S, Weichselbaum RR, An G. Investigation of the essential role of platelet-tumor cell interactions in metastasis progression using an agent-based model. Theoretical Biology and Medical Modelling. 2014; 11(1):17.

42. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther. 2010; 9(5):1092–9. Epub 2010/05/06. https://doi.org/10.1158/1535-7163.MCT-09-1186 PMID: 20442309.